Eli Lilly (LLY) reported $65.2B in revenue for fiscal 2025, +44.7% year on year. That ranks #75 by revenue among 2853 SEC filers and #12 in Healthcare. Net income was $20.6B, a net margin of 31.7%. Revenue has grown 7.3% a year on average since 2011 ($24.3B then). The fiscal 2025 balance sheet shows $112B in total assets, $7.3B in cash and $40.9B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $65.2B | +44.7% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | $25.7B | +102.9% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $20.6B | +94.9% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $16.8B | +90.7% | FY20252025-12-31 |
| Capital expenditure | Not reported | — | |
| Total assetsAssets | $112B | +42.9% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $26.5B | +85.9% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $7.3B | +122.4% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $40.9B | +43.3% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $19.8B | $7.4B | Open → |
| Q2 20262026-06-30 | $23.0B | $7.1B | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 9 of 161 companies compared | 31.7% | |
| Operating marginRank 6 of 160 companies compared | 39.5% | |
| R&D as share of revenueRank 24 of 102 companies compared | 20.5% | |
| Cash as share of revenueRank 80 of 160 companies compared | 11.2% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Eli Lilly & Co
- Ticker
- LLY
- Exchange
- NYSE
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0000059478
Filings
- 10-QAug 5, 2026Open filing →
- 10-QApr 30, 2026Open filing →
- 10-KFeb 12, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| HumanaHUM | $130B | $1.2B |
| Johnson & JohnsonJNJ | $94.2B | $26.8B |
| HCA HealthcareHCA | $75.6B | $6.8B |
| Eli LillyLLY | $65.2B | $20.6B |
| MerckMRK | $65.0B | $18.3B |
| PfizerPFE | $62.6B | $7.8B |
| AbbVieABBV | $61.2B | $4.2B |
Eli Lilly compared withHCA HealthcareMerck
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Eli Lilly — Key figures |url=https://companiesranked.com/en/company/eli-lilly |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Eli Lilly — Key figures. CompaniesRanked. https://companiesranked.com/en/company/eli-lillyBibTeX
@misc{companiesranked-en-company-eli-lilly-2026,
author = {{CompaniesRanked}},
title = {{Eli Lilly — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/eli-lilly}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000059478-26-000013 · February 12, 2026
{{cite web |title=Eli Lilly — Key figures — 10-K (0000059478-26-000013) |url=https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-12}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.